Jeffrey Zonder, MD, discusses the efficacy results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.
Jeffrey Zonder, MD
Advertisement
Articles by Jeffrey Zonder, MD
Jeffrey Zonder, MD, discusses the safety results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
